// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Characterization of amoxicillin‐ and clavulanic acid‐specific T‐cells in patients with amoxicillin‐clavulanic acid hypersensitivity reactions

Ariza Veguillas A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Amoclan suspension

Temporal profiling of type 2 airway inflammation markers in nasal mucosal lining fluid following a grass allergen challenge

Ekoff H - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Spanish children with acute FPIES usually tolerate all other food groups

Argiz L - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Validation of food allergy quality of life short forms (FAQLQ‐10) for parents, children and teens

Dunn Galvin A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Improvement in disease‐specific quality of life for peanut‐allergic subjects receiving AR101 maintenance therapy

Hourihane JO - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Basophil and mast cell responses to food allergens in sensitised but tolerant patients are not mediated via the FcgRIIa and FcgRIIb receptors

Mckendry RT - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Congenital disorder of glycosylation 2C

N/A

Perioperative anaphylaxis in children: Etiology, time sequence and patterns of reactivity

Khaleva E - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

Epinephrine

YKL‐40 As biomarker in severe asthma

E Castro MC - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

IgE to epitopes of Ara H 2 enhance the diagnostic accuracy of Ara H 2‐Specific IgE

Hemmings O - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Antiviral immune response deficiency of nasal epithelial cells from asthmatic patients after RV1B infection

Taka S - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon

Association of Late Functional Improvement With 5-Year Post-stroke Outcomes, A Population-based Cohort Study

Aravind Ganesh - International Stroke Conference (ISC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

Long-term Clinical and Health Economic Consequences of Worsened Post-stroke Status in Patients With Pre-morbid Disability

Aravind Ganesh - International Stroke Conference (ISC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

Effect of the Introduction of a New Pathway for Prevention of Venous Thromboembolisim (VTE) Including Neuromuscular Electrical Stimulation (NMES) on Symptomatic VTE on Immobile Stroke Patients

Jodie Williams - International Stroke Conference (ISC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

Aspirin

Low Incidence of Clean Intermittent Catheterization with OnabotulinumtoxinA in Diverse Age Groups of Overactive Bladder Patients and Substantial Improvements in Urinary Symptoms and Quality of Life

Victor Nitti - New England Section of the American Urological Association (NEAUA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Bladder dysfunction

OnabotulinumtoxinA

How Robust are the Results of Urologic Studies? Applying the P-value Fragility Index to Urologic Studies

Kristian Stensland - New England Section of the American Urological Association (NEAUA) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Multicenter Investigation on the Influence of Climate in Penile Prosthesis Infection

Martin S. Gross - New England Section of the American Urological Association (NEAUA) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Workplace Absenteeism Following Robotic and Open Kidney Surgery

Alexander P. Cole - New England Section of the American Urological Association (NEAUA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The AKI-Predict-Score: a new prediction model for acute kidney injury after liver transplantation

M. Kalisvaart - International Hepato-Pancreato-Biliary Association (IHPBA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Acute renal failure

N/A

Fluid therapy and pain management in liver surgery: a worldwide study among liver surgeons and anesthesiologists

T.H. Mungroop - International Hepato-Pancreato-Biliary Association (IHPBA) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predictors for survival in patients undergoing distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): a Pan-European Cohort

M. Korrel - International Hepato-Pancreato-Biliary Association (IHPBA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

Copyright © 2026. QuantiNova All rights reserved